Connective tissue diseases: What does the death of Riquent hold for the future of SLE?
Where this comes from
- Record sourced from PubMed, PMID 19491911.
- Also identified by DOI 10.1038/nrrheum.2009.99.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In clinical trials testing new treatments for systemic lupus erythematosus (SLE), the failure of the 15-year drug development program for riquent (abetimus sodium) is the latest in a string of disappointments for a disease that has seen no new drugs approved in over 50 years.
Medical subject headings
- Lupus Erythematosus, Systemic
- Oligonucleotides